FIELD: immunology.
SUBSTANCE: present invention relates to immunology. Anti-PDL-1 monoclonal antibodies or antigen-binding fragments thereof are disclosed. Invention also discloses a nucleic acid molecule, an expression vector, a host cell, a method for producing the antibody and a hybridoma cell strain. In addition, a conjugate, a bifunctional conjugate and a multi-specific antibody for binding PDL-1 are disclosed, kit for detecting the presence or level of PDL-1 and a pharmaceutical composition for treating and/or preventing. Invention also describes use of the anti-PDL-1 antibody, a binding inhibition method and a method of treating and/or preventing.
EFFECT: present invention can find further application in therapy of tumors or anemia.
57 cl, 30 dwg, 10 tbl, 19 ex
| Title |
Year |
Author |
Number |
| ANTIBODIES AGAINST THE PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF |
2019 |
- Wang, Haibin
- Hu, Feng
- Zhang, Xuan
- Jiao, Jingyu
- Wu, Zhenhua
- Gao, Dong
|
RU2761638C1 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN |
2016 |
- Zheng, Yong
- Li, Jing
- Gololobov, Gennady
- Zhang, Xinhua
- Yang, Baotian
- Tang, Zhewei
- Li, Dong
- Xu, Jianqing
- Wang, Zhuozhi
|
RU2757316C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2016 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2732924C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE |
2020 |
- Fang, Jianmin
- Jiang, Jing
- Li, Shenjun
- Zhao, Guorui
|
RU2783685C2 |
| PD-1 ANTIBODIES AND USE THEREOF |
2016 |
|
RU2722451C1 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION |
2018 |
- Surh, Charles D.
- Lee, Jun-Young
|
RU2745451C1 |
| ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODY IN HETERODIMERIC FORM, SIMILAR IN STRUCTURE TO NATURAL ANTIBODY, AND PRODUCTION THEREOF |
2022 |
- Liu Jiawang
- Yang Yaping
- Zhao Siqi
- Liu Yang
- Song Nanmeng
- Fan Fei
- Su Kaixuan
- Zhang Lanxin
- Wang Jing
- Xu Jiangcheng
- Lee Kyoung Woo
|
RU2825838C1 |
